Sign up
Pharma Capital

Rhinomed’s strong growth and global product expansion reflects maturing business

Rhinomed Ltd (ASX:RNO) chief executive officer Michael Johnson speaks to Proactive Investors about the Melbourne-based tech company’s suite of consumer health products and its recent licencing deal with medical cannabis major Columbia Care.

“We’ve now had six consecutive quarters of growth – this quarter we expect to report our seventh consecutive quarter of growth,” Johnson says.

He continues, “we shipped 229,000 units over the financial year, we expect to significantly grow that over this financial year and that’s certainly funding the company, that’s driving us to what we hope will be breaking even within the next financial year.

“As we grow we can start to move away from reliance purely on equity to looking at more traditional ways of financing the company … which is really reflective of the fact that the business is maturing.”

 

View full RNO profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.